

S 741

Cancer Drug Parity Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Mar 12, 2019

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Mar 12, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/741>

Sponsor

Name: Sen. Smith, Tina [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (19 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Moran, Jerry [R-KS]	R · KS		Mar 12, 2019
Sen. Murphy, Christopher [D-CT]	D · CT		Mar 12, 2019
Sen. Wicker, Roger F. [R-MS]	R · MS		Mar 12, 2019
Sen. Brown, Sherrod [D-OH]	D · OH		Mar 25, 2019
Sen. Murkowski, Lisa [R-AK]	R · AK		Mar 25, 2019
Sen. Hyde-Smith, Cindy [R-MS]	R · MS		Mar 27, 2019
Sen. Klobuchar, Amy [D-MN]	D · MN		Mar 27, 2019
Sen. Boozman, John [R-AR]	R · AR		Apr 1, 2019
Sen. Markey, Edward J. [D-MA]	D · MA		Apr 1, 2019
Sen. Blumenthal, Richard [D-CT]	D · CT		Apr 29, 2019
Sen. Collins, Susan M. [R-ME]	R · ME		Apr 29, 2019
Sen. Baldwin, Tammy [D-WI]	D · WI		May 6, 2019
Sen. Cramer, Kevin [R-ND]	R · ND		May 6, 2019
Sen. Blackburn, Marsha [R-TN]	R · TN		May 21, 2019
Sen. Merkley, Jeff [D-OR]	D · OR		May 21, 2019
Sen. Capito, Shelley Moore [R-WV]	R · WV		Jul 10, 2019
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Jul 10, 2019
Sen. Jones, Doug [D-AL]	D · AL		Sep 30, 2020
Sen. Scott, Rick [R-FL]	R · FL		Sep 30, 2020

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Mar 12, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 1730	Identical bill	Mar 14, 2019: Referred to the Subcommittee on Health.

Summary (as of Mar 12, 2019)

Cancer Drug Parity Act of 2019

This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Actions Timeline

- Mar 12, 2019: Introduced in Senate
- Mar 12, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.